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Supplementary Information 
Supplementary table 1. Steps for high throughput screen 
S. No. Steps for screening Compounds 
1 
In- vitro absorbance based kinetic screen using esterase 
assay 101,000 
2 Compounds with >60% inhibition 436 
3 Secondary screen by cherry-picking the initial hits 71 
4 Validation of inhibitors using dehydrogenase assay 55 
5 Structural classification of compounds 55  
6 Testing specificity against ALDH1A1 and ALDH2 55  
7 IC50 determination for selective inhibitors 2 
8 Selective inhibitors 2 
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Figure S1 (A). Hits from ChemDiv Screen 
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                    IC50 (μM) 
Compound Structure ALDH1A1 ALDH2 ALDH3A1 
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Figure S1 (B). Hits from ChemBridge Screen 
 
 Inhibition at 10 μM 
concentration 
Compound Structure ALDH1A1 ALDH2 ALDH3A1  
IC50 (μM) 
CB1 
 
>50% NI 3.7 
CB2 
 
<20% NI 5.2 
CB12 
 
NI >50% 3.2 
CB13 
 
<20% NI 11.7 
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 % activity left at 10 μM inhibitor 
concentration 
Compound Structure ALDH1A1 ALDH2 ALDH3A1 
CB41 
 
100% (NI) 90%(NI) 45% (I) 
CB35 
 
100% (NI) 86%(NI) 46% (I) 
CB36 
 
93% (NI) 76%(NI) 30% (I) 
CB38 
 
90% (NI) 83%(NI) 40% (I) 
CB40 
 
95% (NI) 67%(NI) 30% (I) 
CB42 
 
100% (NI) 74%(NI) 46% (I) 
CB37 
 
100% (NI) 83%(NI) 30% (I) 
CB26 
 
100% (NI) 88%(NI) 45% (I) 
CB39 
 
100% (NI) 82%(NI) 32% (I) 
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CB11 
 
100% (NI) 96%(NI) 61% (I) 
CB5 
 
107% (NI) 100%(NI) 34% (I) 
CB32 
 
100% (NI) 84%(NI) 36% (I) 
CB16 
 
100% (NI) 100%(NI) 50% (I) 
CB3 
 
71% (NI) 100%(NI) 55% (I) 
CB21 
 
104% (NI) 100%(NI) 58% (I) 
CB23 
 
110% (NI) 94%(NI) 65% (I) 
CB6 
 
112% (NI) 44%(NI) 6% (I) 
CB14 
 
91% (NI) 97%(NI) 47% (I) 
CB4 
 
71% (NI) 100%(NI) 60% (I) 
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CB10 
 
110% (NI) 101%(NI) 58% (I) 
CB27 
 
138% (NI) 91%(NI) 43% (I) 
 
 
 
NI- No inhibition at 10 micromolar concentration 
I - Inhibition at 10 micromolar concentration 
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Figure S2. Calculation of ED50 for A549, SF767 and CCD13Lu cell lines 
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Figure S3 (A). Quantitation of ALDH1A1 expression in A549 cell line 
Serial dilutions of A549 cell lysates (0.5 µg- 22.5 µg) were compared against serial dilutions of 
recombinantly purified ALDH1A1 (5 ng- 250 ng). Purified recombinant ALDH1A1 protein served 
as positive control and GAPDH served as a loading control. 
 
 
 
 
 
Figure S3 (B). Quantitation of ALDH3A1 expression in A549 cell line 
Serial dilutions of A549 cell lysates (0.5 µg- 22.5 µg) were compared against serial dilutions of 
recombinantly purified ALDH1A1 (5 ng- 50 ng). Purified recombinant His-tagged ALDH3A1 
protein served as positive control and GAPDH served as a loading control. 
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Figure S3 (C). Quantitation of ALDH3A1 expression in SF767 cell line 
Serial dilutions of SF767 cell lysates (1 µg- 10 µg) were compared against serial dilutions of 
recombinantly purified ALDH3A1 (50 ng- 300 ng). Purified recombinant His-tagged ALDH3A1 
protein served as positive control and GAPDH served as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
